According to the latest report by IMARC Group “Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global human insulin market size reached US$ 45.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 68.0 Billion by 2028, exhibiting a growth rate (CAGR) of 6.48% during 2023-2028.
Human insulin (HI) is a short-acting insulin that is synthesized in laboratories. Commonly utilized to mimic the function of natural insulin present in humans, it is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli). It is available as a solution and suspension and is required to be injected subcutaneously. It is widely employed for controlling the blood sugar levels of patients with type I and II diabetes.
HI functions by aiding the sugar produced by the human body to move from the blood to other body tissues where it is used for energy. It can additionally stop the liver from producing more sugar. Apart from this, HI also assists in inhibiting hepatic glucose production and improving the protein synthesis of the body.
Request for a free sample copy of this report:
The growing prevalence of obesity and diabetes among individuals due to sedentary lifestyles represents one of the key factors driving the market. Apart from this, there is a significant rise in the demand for biosimilar drugs on account of their cost-effectiveness and higher efficiency, which, in turn, is also supporting the growth of the market. Furthermore, the key players are introducing pen devices and safety pen needles for improved delivery of insulin to the body. This, in confluence with the increasing research and development (R&D) activities, is acting as another growth-inducing factor.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- B. Braun Melsungen AG
- Dickinson and Company (BD)
- Eli Lilly and Company
- Gulf Pharmaceutical Industries (Julphar)
- Novo Nordisk A/S
- Pfizer Inc.
- Groupe Sanofi
- SEDICO Co.
- Wockhardt Limited
- Ypsomed AG
Explore full report with table of contents:
The report has segmented the market on the basis of Product Type, End-User and Region.
Breakup by Product Type:
- Human Insulin Analogs and Biosimilars
- Rapid Acting
- Long Acting
- Human Insulin Biologics
- Short Acting
- Intermediate Acting
- Human Insulin Analogs and Biosimilars
- Delivery Devices
- Reusable Pens
- Disposable Pens
- Pen Needles
- Standard Pen Needles
- Safety Pen Needles
Breakup by Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Retail Stores
Breakup by Disease Type:
- Type I Diabetes
- Type II Diabetes
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal